WO1996041168A1 - Anticorps monospecifiques et leurs procedes d'application - Google Patents
Anticorps monospecifiques et leurs procedes d'application Download PDFInfo
- Publication number
- WO1996041168A1 WO1996041168A1 PCT/US1996/008438 US9608438W WO9641168A1 WO 1996041168 A1 WO1996041168 A1 WO 1996041168A1 US 9608438 W US9608438 W US 9608438W WO 9641168 A1 WO9641168 A1 WO 9641168A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hinos
- antibody
- peptide
- inos
- buffer
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 87
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 12
- 102000001708 Protein Isoforms Human genes 0.000 claims description 11
- 108010029485 Protein Isoforms Proteins 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 238000007423 screening assay Methods 0.000 claims description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 abstract description 49
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 abstract description 49
- 238000003556 assay Methods 0.000 abstract description 35
- 241000282414 Homo sapiens Species 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 22
- 208000006454 hepatitis Diseases 0.000 abstract description 6
- 231100000283 hepatitis Toxicity 0.000 abstract description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 68
- 239000000523 sample Substances 0.000 description 34
- 239000000872 buffer Substances 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 230000027455 binding Effects 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 239000008363 phosphate buffer Substances 0.000 description 15
- 238000003127 radioimmunoassay Methods 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 13
- 241000473945 Theria <moth genus> Species 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000863 peptide conjugate Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 6
- 229960003121 arginine Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229960002173 citrulline Drugs 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000000584 Calmodulin Human genes 0.000 description 5
- 108010041952 Calmodulin Proteins 0.000 description 5
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 5
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 5
- 239000007994 TES buffer Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000013060 biological fluid Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000055708 human NOS2 Human genes 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 238000011533 pre-incubation Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- -1 tissue Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 4
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 4
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 4
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 235000013477 citrulline Nutrition 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 2
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 241000023308 Acca Species 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 101100080274 Mus musculus Nos3 gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000003278 haem Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 240000003177 tenweeks stock Species 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001124986 Mus musculus Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- DAPUDVOJPZKTSI-UHFFFAOYSA-L ammonium nickel sulfate Chemical compound [NH4+].[NH4+].[Ni+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DAPUDVOJPZKTSI-UHFFFAOYSA-L 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008993 bowel inflammation Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940124280 l-arginine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
- C12N9/0075—Nitric-oxide synthase (1.14.13.39)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Definitions
- nitric oxide a reactive, inorganic free radical gas as a molecule contributing to important physiological and pathological processes is one of the major biological revelations of recent times.
- This molecule is produced under a variety of physiological and pathological conditions by cells mediating vital biological functions.
- An example is endothelial cells lining the blood vessels.
- Nitric oxide derived from these cells relaxes smooth muscle and regulates blood pressure and has significant effects on the function of circulating blood cells such as platelets and neutrophils as well as on smooth muscle, both of the blood vessels and also of other organs such as the airways.
- nitric oxide serves as a neurotransmitter in non-adrenergic non-cholinergic neurons.
- nitric oxide appears to be produced in small amounts on an intermittent basis in response to various endogenous molecular signals.
- nitric oxide can be synthesized in much larger amounts on a protracted basis. Its production is induced by exogenous or endogenous inflammatory stimuli, notably endotoxin and cytokines elaborated by cells of the host defense system in response to infectious and inflammatory stimuli. This induced production results in prolonged nitric oxide release which contributes both to host defense processes such as the killing of bacteria, parasites and viruses as well as pathology associated with acute and chronic inflammation in a wide variety of diseases.
- nitric oxide synthases which utilize the amino acid arginine, molecular oxygen and NADPH as co-substrates has provided an understanding of the biochemistry of this molecule and provides distinct pharmacological targets for the modulation of the synthesis of this mediator, which should provide significant beneficial effects in a wide variety of diseases.
- Nitric oxide and L-citrulline are formed from L-arginine via the dioxygenase activity of specific nitric oxide synthases (NOSs) in mammalian cells.
- NOSs fall into two distinct classes, constitutive NOS (cNOS) and inducible NOS (iNOS). Three isoforms of NOS have been identified comprising two cNOS isoforms and one iNOS isofoim. The two cNOS isoforms are characterized as follows:
- a constitutive, Ca ++ /calmodulin dependent enzyme located in the endothelium (ecNOS or NOS 3), that releases NO in response to receptor or physical stimulation
- a constitutive, Ca ++ /calmodulin dependent enzyme located in the brain (ncNOS or NOS 1) and elsewhere, that releases NO in response to receptor.
- NOS 2 The inducible NOS isoform (NOS 2) is characterized as follows:
- a Ca ++ independent enzyme which is induced after activation of vascular smooth muscle, macrophages, hepatocytes, endothelial cells, chondrocytes, and a large number of other cells by endotoxin and cytokines. Once expressed, this inducible NO synthase produces NO in relatively large amounts for long periods of time.
- Spectral studies of both the mouse macrophage iNOS and rat brain ncNOS have shown that these enzymes (which have been classified as P-450-like from their CO-difference spectra) and amino acid sequence homology contain a heme moiety.
- the structural similarity between NOS and the P-450/flavoprotein complex suggests that the NOS reaction mechanism may be similar to P-450 hydroxylation and/or peroxidation.
- NOS belongs to a class of flavohemeproteins which contain both heme and flavin binding regions within a single protein in contrast to the multiprotein NADPH oxidase or Cytochrome P-450/NADPH Cyt c reductase complexes.
- NOS 1 and NOS 3 Two distinct cDNAs accounting for the activity of NOS 1 and NOS 3 in man have been cloned, one for NOS 1 (Nakane et. al., FEBS Letters, 316, 175-182, 1993) which is present in the brain and a number of peripheral tissues, the other for an enzyme present in endothelium (NOS 3) (Marsden et. al, FEBS Letters, 307, 287-293, 1992). This latter enzyme is critical for production of NO to maintain vasorelaxation.
- the second class of enzyme, iNOS or NOS 2 has been cloned from human liver (Geller et.
- this enzyme is induced upon exposure to cytokines such as gamma interferon (IFN- ⁇ ), interleukin-l ⁇ (IL-l ⁇ ), tumor necrosis factor (TNF-oc) and LPS (lipopolysaccharide).
- cytokines such as gamma interferon (IFN- ⁇ ), interleukin-l ⁇ (IL-l ⁇ ), tumor necrosis factor (TNF-oc) and LPS (lipopolysaccharide).
- IFN- ⁇ gamma interferon
- IL-l ⁇ interleukin-l ⁇
- TNF-oc tumor necrosis factor
- LPS lipopolysaccharide
- Endothelium derived relaxation factor has been shown to be produced by NOS 3 (Moncada et. al., Pharmacol. Reviews, 43, 109-142, 1991). Studies with substrate analog inhibitors of NOS have shown a role for NO in regulating blood pressure in animals and blood flow in man, a function attributed to NOS 3. NO has also been shown to be an effector of the cytotoxic effects of activated macrophages (Nathan, FASEB J., 6, 3051-64, 1992) for fighting tumour cells and invading microorganisms (Wright et al., Card. Res., 26 ,48-57, 1992 and Moncada et al., Pharmacological Review, 43, 109-142, 1991). It also appears that the adverse effects of excess NO production, in particular pathological vasodilation and tissue damage, may result largely from the effects of NO synthesized from the NOS 2.
- NO generated by NOS 2 has been implicated in the pathogenesis of inflammatory diseases.
- hypotension induced by LPS or TNF- ⁇ can be reversed by NOS inhibitors and reinitiated by L-arginine (Kilbourn et. al., PNAS, 87, 3629-32, 1990).
- Conditions which lead to cytokine-induced hypotension include septic shock, hemodialysis (Beasley and Brenner, Kidney Int., 42, Suppl., 38, S96--S100, 1992) and IL-2 therapy in cancer patients (Hibbs et. al, J. Clin. Invest., 89, 867-77, 1992).
- NOS 2 is implicated in these responses, and thus the possibility exists that a NOS inhibitor would be effective in ameliorating cytokine-induced hypotension.
- Recent studies in animal models have suggested a role for NO in the pathogenesis of inflammation and pain and NOS inhibitors have been shown to have beneficial effects on some aspects of the inflammation and tissue changes seen in models of inflammatory bowel disease, (Miller et. al, J. Pharmacol. Exp. Ther., 264, 11-16, 1990) and cerebral ischemia and arthritis (Ialenti et. al, Br. J. Pharmacol ., 110, 701-6, 1993; Stevanovic-Racic et al., Arth. & Rheum., 37, 1062-9, 1994).
- transgenic mice deficient in NOS 1 show diminished cerebral ischemia (Huang et. al, Science, 265, 1883-5, 1994).
- cytokines such as TNF, IL-1 and IL-2
- cytokine -inducing agents as an adjuvant to short term immunosuppression in transplant therapy.
- compounds which inhibit NO synthesis may be of use in reducing the NO concentration in patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition, for example adult respiratory distress syndrome (ARDS) and myocarditis.
- ARDS adult respiratory distress syndrome
- myocarditis myocarditis
- the antibodies of the present invention are useful in the development, evaluation and production of medicaments for the treatment of patients suffering from conditions which are mediated by hiNOS.
- the antibodies of the present invention are useful for diagnosing and monitoring the treatment of a number of diseases in which increased iNOS has been implicated. The implication of these diseases is well documented in the literature.
- FIG. 1 The titer of the peptide-specific antibody in immunized rabbits is shown.
- FIG. 3 The competitive displacement of radiolabelled peptide from the antibody by unlabelled peptide is shown.
- FIG. 4 The antibody concentration and saturation time for peptide binding is shown.
- FIG. 5 The displacement of radiolabelled peptide from the antibody by hiNOS is shown.
- FIG. 6 Monitoring of column chromatographic steps in the purification of hiNOS is shown.
- Figure 7 Western blot analysis is shown for the antibody, and that the detection of hiNOS is blocked by the competing peptide.
- FIG. 8 Western blot analysis is shown demonstrating that the antibody recognizes recombinantly produced hiNOS.
- FIG. 9 Immunohistochemical staining of hiNOS in liver tissue sample from a hepatitis patient is shown.
- Figure 10 Inhibition of hiNOS staining by preincubation with competing peptide in a tissue sample adjacent to that in Figure 9 is shown.
- Figure 1 1 Lack of inhibition of hiNOS staining by preincubation with a noncompeting iNOS-related peptide is shown in a tissue sample adjacent to that in Figure 9.
- Figure 12 Immunohistochemical staining of hiNOS in an intestine tissue sample from a patient with U.C.
- Figure 13 Immunohistochemical staining of hiNOS in a colon tissue sample from a patient with Crohn's Disease.
- Figure 14 Inhibition of hiNOS staining by preincubation with a competing peptide in a tissue sample adjacent to that in Figure 13.
- the present invention is drawn to monospecific antibodies which bind to specific portions of human inducible nitric oxide synthase (hiNOS) and fragments thereof.
- hiNOS human inducible nitric oxide synthase
- the quantity of hiNOS as well as the presence or absence of hiNOS is measured, for example, in a classical RIA or by classical immunolocalization techniques.
- the antisemm detects hiNOS in, for example, clinical tissue samples.
- the antiserum is used to detect or quantify hiNOS in: (a) models in which endogenous synthesis is stimulated by various cytokines or other stimuli; (b) in the diagnosis of various human diseases including those described herein; and (c) in monitoring the course of treatment of hiNOS-mediated diseases, including those described herein.
- Use of this antibody also allows the evaluation of hiNOS modulators in various pharmacokinetic/pharmacological animal models as well as in various human diseases, including those described herein.
- the present invention is directed to the detection, quantitation and localization of hiNOS and fragments thereof as a measure of hiNOS activity.
- the present invention is also directed to an assay system to evaluate the potency of hiNOS modulators in vivo.
- modulation as used herein is defined as the increase or decrease in the amount of hiNOS protein.
- modulator as used herein is defined as a substance or substances which directly or indirectly causes the modulation of hiNOS as defined above.
- the quantitation of hiNOS and fragments thereof may be useful in the diagnosis of various diseases including but not limited to those described herein.
- the identification of hiNOS inhibitors may lead to the development of drugs for the treatment of diseases including, but not limited to, those described herein.
- the present invention is directed to monospecific antibodies which detect hiNOS and polypeptide fragments thereof, but do not detect other NOS isoforms or non-human iNOS.
- One way to monitor hiNOS levels in situ is to assay for hiNOS protein or degradation products thereof. Since hiNOS is involved in a large number of human diseases, including those described herein, the present invention is focused, in part, on developing reagents to quantify hiNOS for this purpose. This is the first time that reagents have been developed to qualify and quantify the presence and/or absence of hiNOS in clinical specimens. To date, general immunological and other assays are used to quantify hiNOS. These assays do not detect denatured hiNOS molecules.
- the antisera described herein not only specifically recognize hiNOS, but also recognize denatured hiNOS. Using these antisera, hiNOS and carboxyl-terminal fragments thereof can be specifically detected, quantified and localized in a wide variety of physical conditions, such as Western blot and in tissue samples.
- the antibodies and assays of the present invention for hiNOS are used as a diagnostic tool to demonstrate increased or decreased levels of hiNOS in various diseases as well as to monitor the efficacy of specific and selective hiNOS modulators in various animal models and man.
- hiNOS modulator compound efficacy is evaluated by quantifying and/or determining the presence or absence of hiNOS. Therefore, assays to monitor both the quantity and/or presence or absence of hiNOS are useful to characterize hiNOS modulators.
- the hiNOS amino acid sequence has been identified by Geller et al (1993), P.N.A.S., 90, pp 3491-3495.
- the peptides around the hiNOS carboxy-terminal seven amino acids are synthetically prepared and polyclonal antisera against those peptides are generated to use as immunoreagents in the assays of the present invention.
- Monospecific antipeptide antibodies are generated which recognize the carboxy-terminal seven amino acids of hiNOS. These antibodies are used to develop radioimmunoassays (RIA) to quantify the hiNOS molecule at this site. These antibodies recognize hiNOS in a wide variety of samples and under a variety of physical conditions.
- RIA radioimmunoassays
- the assays are used to detect and quantify hiNOS in human tissue, synovial fluid, blood, urine or other biological fluids, and Western blots.
- the assay has a limit of detection of about 50 frnoles in Western blots.
- Monospecific antibodies to hiNOS are purified from mammalian antisera containing antibodies reactive against hiNOS or are prepared as monoclonal antibodies reactive with hiNOS using the technique of Kohler and Milstein, Nature 256: 495-497 (1975).
- Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogeneous binding characteristics for hiNOS without binding to the other NOS isoforms or non-human iNOS.
- Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the hiNOS, as described above.
- the hiNOS specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with rabbits being preferred, with an appropriate concentration of hiNOS or a synthetic peptide conjugate based on sequences in this fragment either with or without an immune adjuvant.
- Preimmune serum is collected prior to the first immunization.
- Each animal receives between about 0.1 ⁇ g and about 1000 ⁇ g of hiNOS or peptide conjugate associated with an acceptable adjuvant.
- acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA.
- the initial immunization consists of hiNOS or synthetic peptides based on the C-terminus thereof conjugated to bovine thyroglobulin in, preferably, Freund's complete adjuvant injected at multiple sites either subcutaneously (SC), intramuscular (IM), intraperitoneally (IP) or a combination of the above.
- SC subcutaneously
- IM intramuscular
- IP intraperitoneally
- the hiNOS or synthetic peptides may also be conjugated to other carrier molecules which include those known in the art, such as keyhole limpet hemocyanin and BSA.
- Each animal is bled at prescheduled regular intervals, to determine antibody titer.
- the animals may or may not receive booster injections following the initial immunization.
- animals with no response or low titers are given booster injections.
- These animals receiving booster injections are generally given an equal amount of the hiNOS or peptide conjugates in Freund's incomplete adjuvant by the same route.
- Booster injections are given at about three week intervals until maximal titers are obtained.
- the animals are bled, the serum collected, and aliquots are stored at about -20°C.
- Monoclonal antibodies (mAb) reactive with hiNOS or peptide conjugates are prepared by immunizing inbred mice, preferably Balb/c, with hiNOS or peptide conjugates.
- the mice are immunized by the IP or SC route with about 0.1 ⁇ g to about 10 ⁇ g, preferably about 1 ⁇ g, of hiNOS or peptide conjugates in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred.
- the mice receive an initial immunization on day 0 and are rested for about 3 to 30 weeks.
- Immunized mice are given one or more booster immunizations of about 0.1 to about 10 ⁇ g of hiNOS or peptide conjugates in a buffer solution such as phosphate buffered saline by the intravenous (IV) route.
- Lymphocytes from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art.
- Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas.
- Fusion partners may include, but are not limited to: mouse myelomas P3/NS 1/Ag 4- 1 ; MPC- 11 ; S- 194 and Sp 2/0, with Sp 2/0 being preferred.
- the antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%.
- Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles medium (DMEM) by procedures know in the art.
- DMEM Dulbecco's Modified Eagles medium
- Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using hiNOS or peptide conjugates as the antigen.
- SPIRA solid phase immunoradioassay
- the culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb.
- Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press, 1973.
- Monoclonal antibodies are produced in vivo by injection of pristane primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x l ⁇ 6 to about 6 x 106 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.
- In vitro production of anti-hiNOS mAb is carried out by growing the hydridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb.
- the mAb are purified by techniques known in the art.
- Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of hiNOS in body fluids or tissue and cell extracts.
- the antibodies are useful in the production of a diagnostic assay system for the detection and measurement of hiNOS which is involved in the diseases described herein, and other diseases, from analysis of the patients tissues or biological fluids.
- the antibodies are useful for the immunolocalization of hiNOS in biopsy/tissue samples. Such analysis allows the determination of sites of hiNOS activity in situ.
- hiNOS modulators To evaluate the in vivo or in vitro efficacy of hiNOS modulators, patients or cells in culture are treated with hiNOS modulators and the level of hiNOS is quantified using the immunoassays of the present invention, including the RIA and Western blots, as a monitor of hiNOS activity. Patients or cells in culture are treated with hiNOS modulators and the amount of hiNOS in the cells, cell extracts, conditioned medium, tissue, blood, or other biological fluid is detected or quantified using the immunoassays of the present invention, including the RIA or Western blot. The amount of hiNOS modulation is calculated as a percentage of the hiNOS with modulator treatment as a proportion of hiNOS without modulator treatment.
- the same approach is used to quantify the modulation of hiNOS activity upon treatment with cytokines.
- the same assay is used to evaluate treatment progress in human hiNOS-mediated diseases by monitoring the modulation of hiNOS in tissues, blood or other biological fluids. This modulation is determined by quantifying the level of hiNOS prior to drug treatment followed by quantitation of the hiNOS level during or after drug treatment.
- This assay is also used to quantify the level of hiNOS in tissues, blood or other biological fluids from animal models of hiNOS- mediated diseases as well as humans.
- the antiserum generated against hiNOS is also used to localize, detect or quantify hiNOS by standard immunolocalization techniques. This approach is used to localize sites of hiNOS activity in situ. In the presence of a modulator, hiNOS levels may be either reduced or elevated compared to levels of hiNOS in samples not treated with modulator or prior to treatment. By comparing the distribution of hiNOS in tissues from patients treated with drug (hiNOS modulator) to tissue from patients not treated with drug or pretreatment, the distribution of hiNOS modulation is localized and monitored. This approach is used in tissues from humans or animals injected with hiNOS modulators, humans or animals injected with cytokines to generate hiNOS endogenously, or any disease mediated by hiNOS in humans or animal models.
- the components of the assay described herein can easily be assembled into a package or kit.
- the components can be used to coat the surface of a substratum or solid carrier.
- Suitable carrier materials include cellulose, cross linked dextrose, silicone rubber, microcrystalline glass, and a wide variety of plastics.
- the most common types of carriers or substratum are plastics including but not limited to polyethylene, polyvinyl chloride, polyamides, polystyrene, polypropylene and other polymers.
- the carrier or substratum can be formed into various shapes including but not limited to tubes, dishes, plates, multiwell plates, beads or any vessel.
- the assay components may be covalently bonded to the carrier or substratum, cross-linked, or physically coupled thereto.
- Kits suitable for immunodiagnosis, or for any other purpose described herein containing the appropriate reagents are constructed by packaging the appropriate materials, including the antibodies of the present invention, in a suitable container along with the remaining reagents and materials required for the assay. A set of instruction should be included.
- the column was constructed using a rabbit polyclonal antipeptide antibody raised against the peptide immunogen, a sequence cognate to the C-terminus of human hepatocyte iNOS.
- the column binds the active dimer and inactive monomer forms and both were eluted with a 25 uM solution of the cognate peptide.
- Immunoblots and silver-stained SDS-PAGE analysis of the protein exhibited a band with an apparent molecular weight of 130 kDa.
- the specific activity varied from 60-200 nmoles citrulline/min/mg at 37°C as measured in an HPLC-based ⁇ H-arginine to ⁇ H-citrulline conversion assay (ACCA).
- Cell cultures supplemented with serum and delta-amino levulinic acid yielded enzyme with the highest specific activity.
- Peptide antigens and peptide probes were synthesized using (Fmoc) fluorenylmethoxy-carbonyl chemistry on an ABI 430A peptide synthesizer (Applied Biosystems, Inc.). Peptide acids were synthesized on standard Wang resins, while peptide amides were synthesized on Rink amide resins. Syntheses were carried out according to the FastMocTM protocols for benzotriazoltetramethyl-uronium hexafluorophosphate (HBTU) mediated couplings described in detail in the ABI 430A Synthesis Notes (Applied Biosystems, 1992).
- HBTU benzotriazoltetramethyl-uronium hexafluorophosphate
- Peptidyl resins were cleaved and deprotected with TFA according to the procedures described in the ABI 430A Operators Manual. Peptides were purified by reversed phase HPLC on a Waters DeltaPak C18 column with an acetonitrile gradient of 2-50% in aqueous 0.1% trifluoroacetic acid (TFA). Purity of individual peptides was assessed by reversed phase HPLC on an Applied Biosystems Spheri-5 C18 column. The structure of the peptides was confirmed by mass spectrometry utilizing either fast atom bombardment or electrospray ionization. The primary antigen associated with the carboxyl terminus of hiNOS is synthesized with four additional amino acid residues.
- Cysteine-arginine-norleucine-ornithine is attached to the synthetic peptide Ser-Leu-Glu-Met-Ser- Ala-Leu (SEQ.ID.No.:l) to give the following antigen: Cys-Arg-Nle-Orn-Ser-Leu-Glu-Met-Ser-Ala-Leu (SEQ. ID. NO.:2).
- the cysteine is a linking amino acid because it allows the antigen to be linked or attached to an immunogenic carrier.
- the norleucine was added as an internal marker to determine the actual number of antigen molecules attached to a single immunogenic carrier.
- the arginine and ornithine were added to increase the aqueous solubility of the peptide.
- N-acetylated peptide Peptide (SEQ. ID. NO.: 2) was dissolved in a 1.0-ml solution of 70:30 methanol :acetic anhydride and incubated for 10 min at 25 °C. This was then diluted with an equal volume of H2 ⁇ followed by evaporation to dryness. Reconstitution in H2O and evaporation was repeated twice to remove excess acetic acid. The resulting powder was redissolved in 0.075M PBS-azide with a pH of 7.0. EXAMPLE 2
- Attachment of the antigenic peptides to the carrier protein was carried out according to a modification of the method of Lerner et al, Proc. Nat. Acad. Sci. USA 78: 3403-3407 (1981) using the heterobifunctional coupling reagent, Sulfo-MBS (Pierce Chemical Co.).
- the peptide antigen was attached to the carrier bovine-thyroglobulin (TG), by combining 10 mg of TG dissolved in 2.5 ml degassed phosphate buffer, 20 mM, pH 8.0 with 4.2 mg Sulfo-MBS and incubating for 30 minutes at room temperature with stirring.
- TG carrier bovine-thyroglobulin
- the carrier-coupling reagent mixture was then applied to a disposable PD-10 Sephadex G-25 column (Pharmacia) which had been equilibrated with de-gassed 50 mM phosphate buffer, pH 7.0.
- a small vial containing 6 micromoles of the purified, lyophilized peptide antigen was placed under the column outlet and the activated TG fraction was eluted into the vial with an additional 3.5 ml of the pH 7.0 buffer.
- the peptide antigen-activated carrier complex was allowed to react overnight at 4°C with gentle stirring.
- the degree of coupling for the peptide-carrier immunogen conjugate was determined by removing an aliquot of the final reaction mixture and passing it through a PD-10 Sephadex G-25 column equilibrated with PBS to remove any remaining free peptide and/or reaction by-products.
- Antigen probes to determine antibody specificity and to evaluate the presence and amount of hiNOS were synthesized by the process described herein.
- Antigenic probes used to determine the presence and amount of hiNOS were designed to include a tyrosine residue at the terminus distal to the epitope so that the probe could be coupled to 125l.
- the initial probe used to determine antibody titer was a synthetic peptide based on the amino acid sequence of hiNOS, Ser- Leu-Glu-Met-Ser- Ala-Leu [SEQ.ID.NO.:l], plus an amino terminal tyrosine residue.
- Radioiodination of the assay probe was accomplished by reaction with chloramine T.
- the peptide probe was dissolved in water at a concentration of 220 ⁇ g/ml.
- a 50 ⁇ l volume of this solution (containing 1 1 ⁇ g) was added to 10 ⁇ l of 0.5 M phosphate (K+) buffer, pH 7.5 and then combined with 2mCi of 125i Na and 10 ⁇ l freshly prepared chloramine T (0.1 mg/ml) in water.
- the mixture was allowed to react for 30 seconds and the reaction was stopped with 10 ⁇ l of 1 mg/ml Nal plus 1 mg/ml sodium thiosulfate.
- the radioiodinated probe was purified by HPLC using a Supelco C-8 column (0.4 x 25 cm).
- the iodinated probe was eluted by a 35 minute 1% per-minute gradient of 99% eluant A-1% eluant B to 36% eluant A-64% eluant B at a flow rate of 1 ml per minute.
- Eluant A consisted of 0.1 % trifluoroacetic acid in water and eluant B consisted of 0.1 % trifluoroacetic acid in acetonitrile.
- New Zealand White Rabbits were immunized with the peptide immunogen.
- the initial immunizations employed 333 ⁇ g of the immunogen conjugate per 1 ml Freund's complete adjuvant (FCA) given intramuscularly per rabbit.
- FCA Freund's complete adjuvant
- animals were again given 333 ⁇ g of immunogen in FCA and on day 35 a total of 333 ⁇ g of immunogen was given subcutaneously at 6-10 sites.
- the animals were bled, then boosted with 333 ⁇ g of immunogen.
- animals were again boosted and 10 days later bled. This boosting and bleeding schedule was continued 3-5 times to obtain an adequate supply of antiserum. All antisera were stored at -20°C.
- a specific antibody which recognizes only hiNOS was produced. This antibody was designated N053 and has been utilized in a wide variety of immunoassays and immunopurification processes. High titer antisera was produced in rabbits, which reached titers of approximately 1:500,000 ( Figure 1). Titers were greater than 1:50,000 generally.
- YRASLEMSAL [SEQ.ID.NO.:3] (also referred to herein as N054) was radioiodinated utilizing the iodogen method. Briefly, YRASLEMSAL [SEQ.ID.NO.:3] (0.2 nmoles) was incubated for 12-15 minutes with 400-500 mCi Nal25j m __ ⁇ iodogen (Pierce Chemical Co.) coated microfuge tube. The radiolabeled peptide was separated from the unreacted Na ⁇ 5j by chromatography on a 5 ml bed volume G-10 Sephadex column eluted with 25% acetic acid containing 0.1 % Triton X-100.
- the non-retained material which contained the radiolabeled peptide, was lyophilized to dryness.
- the 125 ⁇ _p e ptide was further purified on RP-HPLC.
- the peptide was reconstituted into a minimal volume of H2 ⁇ and injected onto a Zorbax C8 reverse phase column and eluted with an acetonitrile/H2 ⁇ gradient at 1 ml/minutes.
- Buffer A was 0.1 % TFA in H2O and buffer B was 0.1 % TFA in acetonitrile.
- the column was eluted for 10 minutes with 90% buffer A/10% buffer B; for 10 minutes with a linear gradient to 70% buffer A/30% buffer B; and for 30 minutes with 70% buffer A/30% buffer B.
- An RIA buffer solution was prepared containing NaCl 100 mM, 47 mM NaHP04, 0.5% bovine serum albumin, 0.1% Tween 20 and 0.1% NaN3. The pH was adjusted to 7.2 ⁇ 0.1. It is readily apparent that a variety of other buffer solutions are suitable for use in the assay described herein and the success of the assay is not limited to the above buffer.
- Protocol 1 The initial experiments were performed in 12x75 mm borosilicate disposable culture tubes (Fisher Scientific) The assay was conducted in a total volume of 300 ⁇ l of the RIA buffer. One hundred microliters of RIA buffer or standards or samples diluted in this buffer were mixed with 100 ⁇ l of N053 antiserum (final dilution 1:60,000) and 100 ul of the 125 I-probe (-30,000 CPM) and incubated overnight at 4°C.
- the synthetic peptide YRASLEMSAL [SEQ.ID.NO.:3] (N054) was used to generate the standard curve.
- a 10 nM stock solution of standard peptide was prepared in the RIA buffer and stored frozen at -20°C.
- 10 concentration standards (2-1000 fmoles/100 ⁇ l) were prepared by serially diluting 100 ⁇ l aliquots of the stock solution 1 :2 in the RIA buffer 9 times. Therefore, the standard curve concentrations of peptide were 2, 4, 8 16, 31.25, 62.5, 125, 250, 500, and 1000 fmoles/100 ⁇ l. Tubes without standard (to measure the total amount of antiserum binding) and tubes without antiserum (to measure the total amount of radioactivity added and background) were also included. The standard curve is performed in duplicate and samples analyzed with multible dilutions.
- the antibody-bound radiolabeled probe was separated from unbound radiolabeled material by an anti-rabbit-IgG antibody attached to magnetic beads.
- a suspension of BioMag beads goat anti-rabbit IgG (H&L) (PerSeptive Diagnostics, Cambridge MA) was diluted 1 :2 just prior to use with PBS.
- One ml aliquots of the suspension were added to all tubes, except tubes not containing antiserum which were used for the determination of total radioactivity, and incubated at room temperature for 5 minutes. During the 5 minute incubation period, the tubes containing beads were transferred to a rack with compression springs (Amersham, Arlington Heights, IL) which securely hold the test tubes.
- the rack was applied to a magnetic plate (Amersham, Arlington Heights, EL) and incubated for an additional 10 minutes. The rack was then inverted and the supernatant fluid containing the unbound 125j_ probe was collected in vermiculite and discarded. The ends of the tubes were blotted onto paper towels. The antiserum bound 125 ⁇ _p r0De peptide was "held" to the bottom of the test tubes by the magnetic field. It is readily apparent that other methods of separating bound probe from unbound probe can be used, such as dextran coated charcoal and double antibody.
- the radioactivity associated with the ⁇ 5 ⁇ _p ro be was determined in a 10-well Cobra II Auto Gamma Counter (Packard Instruments).
- the percent binding of probe to antisera (B/Bo) in the presence of the competitive unlabeled peptide was determined based on the amount bound in the absence of the competitive unlabeled peptide.
- the B/B ⁇ as a function of standard peptide concentration was plotted by a 4-parameter algorithm (Immunofit Packard Instruments).
- the B/Bo of the samples were similarly determined and the concentration of rH- iNOS expressed as frnoles of unlabeled peptide, was determined from the standard curve. Only values falling between 20-80 B/B ⁇ % binding were considered to be valid for calculations.
- the standard curve parameters (EC80, EC50, EC20) and the percent binding were recorded for each assay.
- quality control standard solutions of the standard peptide were run in each assay.
- the quality control standards were required to be within 2 standard deviations of mean of the initial 5 assays to be considered valid.
- the RIA has been adapted into a 96-well format using 96- well FlashPlateTM (New England Nuclear Corp.) scintillation proximity counting technology.
- the wells of these plates contain a scintillant that detects radioactivity.
- a radioactive ligand becomes bound to the surface of the wells the scintillant is activated and the amount of radioactivity quantified in a 96 well scintillation counter. Unbound radioligand in solution does not activate the scintillant thus obviating the need to separate "bound versus free" radiolabelled probe in RIA protocols.
- These plates were precoated with sheep-anti-rabbit IgG as a capture reagent.
- Antiserum N053 was diluted (usually 1 :60,000) into Dulbecco's phosphate buffered saline (PBS). Aliquots, 200 ul, were added to wells of the Flashplates and incubated for 18 hours or for as long as 1 week at 4°C. Two wells on the plate received PBS only to determine non-specific binding. All wells were rinsed with 200 ul of RIA buffer and then incubated with 200 ul of this buffer for at least 1 hour to "block" non-antiserum coated areas of the well. In an identical manner as described in Protocol 1 , the synthetic peptide YRASLEMSAL [SEQ.ID.NO.:3] (N054) was used to generate the standard curve.
- PBS Dulbecco's phosphate buffered saline
- concentration standards (2-1000 fmoles/100 ml) were prepared by serially diluting 100 ml aliquots of the stock solution 1 :2 in the RIA buffer 9 times.
- the assay was conducted in a total volume of 200 ⁇ l of the RIA buffer.
- the antibody titer for the most active rabbit antisera against the peptide antigen was determined using a radioimmunoassay such as protocol 1 ( Figure 1 ).
- the antiserum was diluted in phosphate buffered saline with dilutions ranging from 1 :10,000 to 1 :500,000 per 100 ⁇ l.
- the diluted antiserum was contacted with 125i-Tyr-Ser-Leu-Glu-Met- Ser-Ala-Leu (SEQ.ID.No.:3) radiolabeled probe.
- the radioactive probe was diluted in assay buffer to yield approximately 30,000 cpm per 100 ⁇ l aliquot.
- the assay volume was made up to 200 ⁇ l by the addition of 100 ⁇ l assay buffer. All determinations were made in duplicate.
- the antibody was shown to be specific for the peptide YRASLEMSAL (SEQ.ID.NO.:3), and that the carboxyl-terminal leucine is required for antibody recognition by the ability of the radiolabelled peptide to be displaced by unlabelled peptide ( Figures 2 and 3).
- the sensitivity of the assay to amino acid substitutions at the carboxy- terminal leucine further demonstrates the specificity of this antibody for hiNOS ( Figure 2).
- the RIA's were performed in test tubes with an 18 hour (Protocol 1) incubation as well as in Flashplate wells with a 2.5 hour incubation (Protocol 2).
- the competitive displacement of the peptide did not appreciably change as a function of incubation time.
- the hepatocytes were then lysed into a buffer containing protease inhibitors and the amount of hiNOS was determined in the RIA at four dilutions. The results are shown in Table 1 and demonstrate a substantial increase in hiNOS following cytokine-stimulation of the hepatocytes.
- the immunostaining was specific for hiNOS and was demonstrated by Western blot analysis. No staining of mouse iNOS, or the other constitutive isotypes of human NOS was seen on Western blots.
- the antibody was also able to detect hiNOS in 3T3 cells producing hiNOS, but not in 3T3 cells not producing hiNOS (Figure 8). Protein concentration was determined using the method of Bradford (Bradford M.M. 1976, Analytical Biochemistry, 73, p 248) with bovine serum albumin as the standard.
- Cells or tissues are treated with a modulator of hiNOS activity prior to collection of a sample for hiNOS evaluation.
- Control cells or tissues are treated with vehicle alone prior to collection of a sample for hiNOS evaluation.
- After a period of time sufficient to allow the modulator to produce its effect of hiNOS modulation the samples for analysis are collected.
- the level of epitope in the sample is determined by the immunoassays disclosed herein, including the RIA.
- Upon treatment with a hiNOS modulator there is an increase or reduction in the amount of epitope in the treated samples compared to untreated samples. The result is confirmed by a standard enzyme activity assay. NOS activity is measured as the formation of L-[2,3,4,5-3H]Citrulline from L-[2,3,4,5-3H]Arginine.
- the incubation buffer (100 ⁇ L) contains: 100 mM TES, pH 7.5, 5 ⁇ M FAD, 5 ⁇ M FMN, 10 ⁇ M BH4, 0.5 mM NADPH, 0.5 mM DTT, 0.5 mg/mL BSA, 2 mM CaC12, 10 ⁇ g/mL calmodulin (bovine), 1 ⁇ M L-Arg, 0.2 ⁇ Ci L-[2,3,4,5-3H]Arg, and the modulator in aqueous DMSO (max. 5 %).
- the reaction is initiated by addition of enzyme.
- Immunoaffinity column construction and use The ImmunoPure IgG Orientation Kit protocol was followed in toto except for the following modifications: 6.0 ml of antiserum was diluted with an equal volume of 0.075 M phosphate buffered saline -0.02% NaN3. 1 ml of 3.0 mg/ml bovine thyroglobulin in PBS-azide was added and allowed to stand for 18 hours at 4°C. The solution was centrifuged at 3000 rpm for 10 minutes and the precipitate discarded.
- the supernate was added to a 25- ml bed of Protein- A agarose packed in a Bio-Rad glass column, capped, slurried and rotated end-over-end for 30 minutes at 25 °C. Following 10 volumes of PBS-azide wash, the column was mixed with 15 ml containing 100 umol of N-acetylated peptide for 30 minutes and thereafter drained and washed with 2 volumes of coupling buffer (0.2 M triethanolamine, pH 8.2 with 0.02% NaN3. 100 mg of DMP
- the acetylation of the cognate peptide was intended to prevent possible crosslinking of its free N-terminus to the antibody. From earlier specificity studies, no loss of recognition by the antibody after modifications distal to the C-terminus of the peptide was seen. Following the preincubation, excess peptide was removed by washing the column with 2 volumes of the crosslinking buffer, then DMP was added. The resulting column showed high selectivity and binding capacity for the cognate N054 peptide and its acetylated form.
- Immunopurification of the enzyme The entire procedure was done at 4°C. Two separate batches of 150-ml 100,000xg crude Sf9 lysates were processed identically. The lysates were diluted with equal volumes of running buffer (20 mM TES, pH 7.4, 1 mM CHAPS, 100 ⁇ M BH4, 0.1 mM DTT and 250 mM NaCl) then clarified using a Microgon Filtration System 0.22 micron hollow fiber filters (Laguna Hills, Ca). The clarified lysates were infused onto identical 25-ml columns using
- the columns were regenerated by stripping off the bound cognate N054 peptide using 0.1 M sodium citrate of pH 3.0.
- FIG. 6 shows the immunoaffinity purification steps for recombinant human hepatocyte iNOS presented as enzyme activity measured in a 30-minute ⁇ H-arginine to ⁇ H citrulline conversion assay. (Fractions 1-12, flow-throughs; 13-28, wash steps; 29-32, elution steps. (Inset) Silver-stained SDS-PAGE of the purification steps.
- Lane A molecular weight markers
- lane B crude lysate
- lane C flow-through
- lanes D-E wash steps
- lanes F-I fractions 29-32.
- Molecular weight markers are myosin (200,000), ⁇ -galactosidase (116,000), phosphorylase b (97,400), bovine serum albumin (66,000) and ovalbumin (45,000).
- a predominant 130 kDa band was evident in all the eluted fractions, and this profile was identical for both batches. Minor bands were noted at molecular weights above and below the 130 kDa band. By densitometric measurement, the 130 kDa band was deemed >95% pure.
- the immunoaffinity-purified enzyme from the two batches were each diluted 1 :3 with TES buffer containing 0.01 M NaCl up to a total volume of 190 ml. This brought the final salt concentrations to 0.03 M, allowing for binding to a DEAE-5PW ion exchange column.
- a linear gradient of 0.01 M-0.5 M NaCl in TES buffer eluted the enzyme at -0.175 M into a 2.0-ml aliquot while the cognate N054 peptide bound more tightly to the columns and was eluted at the 0.5 M NaCl point.
- This step provided highly concentrated enzyme solutions, with recoveries of -80-90%.
- iNOS Inducible nitric oxide synthase
- Appropriate human tissues were fixed in 10% neutral buffered formalin, paraffin embedded, and 5 ⁇ M sections cut and attached to precoated glass slides (polylysine or Vectabond). Designated slides were treated with proteinase K (Dako Corp; diluted 1 :1 with 0.05M Tris-HCL, pH7.5) for 3 minutes at 23°C. Endogenous peroxidases were blocked with 3% hydrogen peroxide in methanol (10ml 30% peroxide/90 ml methanol) for 20 minutes. The slides were washed three times for one minute in 3 changes of 0.1 M phosphate buffer.
- the sections were treated with 0.1% Triton XI 00 in PBS at 4°C for 5 minutes, washed two times for one minute in several changes of 0.1M phosphate buffer. Endogneous biotin-binding sites were blocked by incubation with the avidin solution (Vector) for 15 minutes at 23°C. The slides were then washed three times for one minute with several changes in 0.1 M phosphate buffer (OXOID tablets pH 7.8) containing 0.2% bovine serum albumin (BSA) and 0.01 % Tween-20 for lhour at 23°C in moist chambers. This buffer is used for all washing steps below unless otherwise indicated.
- Endogenous avidin-binding sites were blocked by incubation with biotin solution (Vector) for 15 minutes at 25°C.
- the slides were then washed three times for one minute with several changes in 0.1 M phosphate buffer.
- Nonspecific binding was blocked for 20 minutes with normal serum obtained from the species used to generate the secondary antibody, and dissolved in 0.1 M phosphate buffer.
- the slides were then washed three times for one minute in several changes of 0.1 M phosphate buffer.
- the sections were then incubated in NO-53 (l-5 ⁇ g/ml in 1% BSA, 0.1 % NaN3 and 0.1M phosphate buffer) for 1 hour at 23°C in moist chambers (for controls, antibodies were incubated with appropriate blocking or control peptides for 1 hour at room temperature, and clarified by centrifugation prior to incubation with the sections).
- the slides were then washed five times for two minutes in several changes of 0.1 M phosphate buffer.
- the sections were postfixed in 3.5% formaldehyde [10ml of 16% formaldehyde (Polysciences) plus 35ml buffer] in 0.1 M phosphate buffer (pH 7.4) for 15 minutes. The slides were then washed three times for two minutes with changes in 0.1M phosphate buffer (pH 7.8).
- Vectastain ABC solution was prepared according to the manufacturer's directions in 0.1 M phosphate buffer (pH 7.8) containing 0.1% bovine serum albumin 30 minutes before use. Slides were stained for 30 minutes at 23°C. The slides were then washed five times for two minutes in changes of 0.1 M phosphate.
- GOD/DAB/Nickel substrate solution was prepared freshly before use according to Shu, S. et al. "The glucose oxidase-DAB nickel method in peroxidase histochemistry of the nervous sytem" in Neuroscience Letters, 85, 169-171 , 1988, as follows: a. Stock solution A: 1.25g Nickel ammonium sulfate in 25 ml 0.2M acetate buffer (pH 6.0). b. Stock solution B: 30 mg 3,3'-diaminobenzidine tetrahydrochloride in 25 ml solution of 0.05%
- the slides were rinsed in 0.1 M acetate buffer (pH 6.0), and sections were incubated in the GOD/DAB/Nickel substrate solution for 10 minutes at 23°C, then the reaction was stopped by washing with 0.1M acetate buffer (pH 6.0). The slides were washed in running tap water for 5 minutes, then counter stained in diluted eosin, dehydrate, cleared and coversliped.
- Figure (9) shows a liver section with a venule containing conspicuous iNOS-positive mononuclear cells that comprise a large intraluminal aggregate (arrow), and are also adherent to the endothelium (arrowheads).
- iNOS staining was performed with 5 ⁇ g/ml NO-53 IgG.
- the iNOS staining of mononuclear cells in an adjacent section was eliminated by pre-absorbing 5 ⁇ g/ml NO- 53 IgG with 50 nM NO-54, the blocking peptide ( Figure 10).
- the background particulate material (arrowheads) was present in unstained sections of this specimen, and is of endogenous origin.
- the iNOS staining of an adjacent section was unaffected by pre-absorbing 5 ⁇ g/ml NO-53 IgG with 50 nM NO-70, a non-blocking control peptide lacking the natural C-terminal alanine ( Figure 11 ). Therefore, the labeling of mononuclear cells in human hepatitis is specific for the C-terminal epitope of human iNOS.
- NO-53 antibody detected hiNOS in a section of resected colon from patient who had symptoms of ulcerative colitis for 10 years, when labeled with 2.5 ⁇ g/ml NO-53 IgG ( Figure 12).
- Intense focal iNOS labeling is localized in the epithelium (E) sunounding the villi, and within the inflamed crypts.
- Mononuclear cells in the lamina basement (arrows), and many polymorphonuclear leukocytes within the lumen of inflamed crypts (arrowheads), are also strongly positive for iNOS.
- the NO-53 antibody also detected hiNOS in a section of resected colon from a patient who had Crohn's disease for 27 years, labeled with l ⁇ g/ml NO-53 IgG pre-absorbed with 50nM NO-70 (the non-blocking control peptide) ( Figure 13).
- Intense diffuse iNOS labeling is present throughout the epithelium surrounding the villi (arrow), and within the crypts (arrowheads).
- a section adjacent to that depicted in Figure 13 was labeled with l ⁇ g/ml NO-53 IgG pre-absorbed with 50nM NO-54 (blocking peptide) ( Figure 14).
- Epithelial iNOS labeling has been eliminated, thus attesting to the specificy of the iNOS label in the inflamed epithelium.
- the C-terminal epitope of iNOS specifically recognized by NO-53 has thus been localized in the epithelium, and within the leukocytes of the lamina intestinal and crypt abscesses of 8 patients with ulcerative colitis, and in 9 patients with Crohn's disease.
- No iNOS labeling was observed in the normal colonic epithelium adjacent to the bowel cancers of 5 patients, indicating that epithelial iNOS induction is linked to inflammation.
- the colonic/crypt epithelium maintains the proper ionic balance of the colon, and is the site of continuous generation of new gut lining cells.
- Localization of iNOS at this vital locus in patients throughout the chronic course of inflammatory bowel disease strongly suggests that a potent and selective iNOS inhibitor will be of therapeutic value for the treatment of lower bowel inflammation.
- the specific detection of iNOS in mononuclear cells within the livers of 2 hepatitis patients also indicates that iNOS plays a role in host defense, and thus any selected iNOS inhibitors must be controlled very carefully for the management of chronic inflammatory disease.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96919038A EP0835448A1 (fr) | 1995-06-07 | 1996-06-03 | Anticorps monospecifiques et leurs procedes d'application |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47699195A | 1995-06-07 | 1995-06-07 | |
US08/476,991 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996041168A1 true WO1996041168A1 (fr) | 1996-12-19 |
Family
ID=23894061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008438 WO1996041168A1 (fr) | 1995-06-07 | 1996-06-03 | Anticorps monospecifiques et leurs procedes d'application |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0835448A1 (fr) |
CA (1) | CA2222436A1 (fr) |
WO (1) | WO1996041168A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106645693A (zh) * | 2016-12-28 | 2017-05-10 | 舒斯云 | 一种用于辣根过氧化物酶染色的染色剂及其制备方法、染色组合、应用及标记酶染色试剂盒 |
-
1996
- 1996-06-03 CA CA 2222436 patent/CA2222436A1/fr not_active Abandoned
- 1996-06-03 WO PCT/US1996/008438 patent/WO1996041168A1/fr not_active Application Discontinuation
- 1996-06-03 EP EP96919038A patent/EP0835448A1/fr not_active Withdrawn
Non-Patent Citations (7)
Title |
---|
BIOCHEM. BIOPHYS. RES. COMM., 31 December 1991, Vol. 181, No. 3, SCHMIDT H.H.H.W. et al., "Purification and Characterization of a Human NO Synthase", pages 1372-1377. * |
EUR. J. BIOCHEM., 1993, Vol. 215, RIVEROS-MORENO V. et al., "Nitric Oxide Synthase Structural Studies Using Anti-peptide Antibodies", pages 801-808. * |
JOURNAL OF BIOLOGICAL CHEMISTRY, 04 March 1994, Vol. 269, No. 9, CHARTRAIN N.A. et al., "Molecular Cloning, Structure and Chromosomal Localization of the Human Inducible Nitric Oxide Synthase Gene", pages 6765-6772. * |
JOURNAL OF BIOLOGICAL CHEMISTRY, 05 December 1991, Vol. 256, No. 34, HEVEL J.M. et al., "Purification of the Inducible Murine Macrophage Nitric Oxide Synthase", pages 22789-22791. * |
JOURNAL OF IMMUNOLOGY, 15 July 1987, Vol. 139, No. 2, STUEHR D.J. et al., "Induction of Nitrite/Nitrate Synthesis in Murine Macrophages by BCG Infection, Lymphokines, or Interferon-Gamma-1", pages 518-525. * |
PROC. NATL. ACAD. SCI. U.S.A., 15 April 1993, Vol. 90, No. 8, GELLER D.A. et al., "Molecular Cloning and Expression of Inducible Nitric Oxide Synthase from Human Hepatocytes", pages 3491-3495. * |
PROC. NATL. ACAD. SCI. U.S.A., September 1991, Vol. 88, STUEHR D.J. et al., "Purification and Characterization of the Cytokine-induced Macrophage Nitric Oxide Synthase: An FAD- and FMN-Containing Flavoprotein", pages 7773-7777. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106645693A (zh) * | 2016-12-28 | 2017-05-10 | 舒斯云 | 一种用于辣根过氧化物酶染色的染色剂及其制备方法、染色组合、应用及标记酶染色试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CA2222436A1 (fr) | 1996-12-19 |
EP0835448A1 (fr) | 1998-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hawkes et al. | Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2 | |
AU596952B2 (en) | Peptide anitbodies and their use in detecting oncogene products | |
WO1994017197A1 (fr) | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION | |
JPH09509160A (ja) | Fk−506細胞質ゾル結合蛋白質 | |
EP0175360A2 (fr) | Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes | |
US5387504A (en) | Monospecific antibodies and assay system for detecting stromelysin cleavage products | |
JP3107225B2 (ja) | Pacapに対する抗体およびその用途 | |
JP4374316B2 (ja) | β−アミロイドまたはその誘導体に対する抗体およびその用途 | |
JP2898293B2 (ja) | エンドセリンに対する抗体およびその用途 | |
WO1996039858A1 (fr) | Anticorps monospecifiques et leurs procedes d'utilisation | |
WO1996040785A1 (fr) | Anticorps monospecifiques et leurs procedes d'utilisation | |
EP0835448A1 (fr) | Anticorps monospecifiques et leurs procedes d'application | |
WO1996041190A1 (fr) | Anticorps a specificite unique et leur mode d'emploi | |
KR0145406B1 (ko) | 감마 아트리알 나트륨 이뇨성 폴리펩티드를 인식하는 단일 클론 항체 | |
AU755574B2 (en) | Synthetic peptide immunogens and antibodies thereto | |
US20070014799A1 (en) | Antibody and use of the same | |
US5439795A (en) | Monoclonal antibodies that specifically bind somatotropin binding proteins but not to corresponding somatotropin receptors and methods of use in immunoassays | |
JP4314365B2 (ja) | エンドセリン−2/vicに対する特異的な抗体、作製方法、およびその用途 | |
US7173112B2 (en) | Antibody to GALP and uses thereof | |
JPH06125784A (ja) | モノクローナル抗体,ハイブリドーマ,その製造法および用途 | |
KR900008014B1 (ko) | 펩타이드 항체의 제조방법 | |
US7598351B2 (en) | Antibody and use thereof | |
US7342105B2 (en) | Antibody and use thereof | |
JP4339564B2 (ja) | 抗体およびその用途 | |
US20040197823A1 (en) | Compositions and methods for aa4rp assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2222436 Country of ref document: CA Ref country code: CA Ref document number: 2222436 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 984737 Date of ref document: 19971204 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996919038 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996919038 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996919038 Country of ref document: EP |